SOLARA ACTIVE PHARMA SCIENCES
|
|
BOM : 541540     NSE : SOLARA     | |
LT :  
    Long Term Analysis
Fundamentals : Average
Valuation : Bad [Stock is Expensive] Debt : High |
Updated: |
ST :  
    Short Term Analysis
Quarterly Earnings Trend : Upward
Price Momentum : Upward Pledged Shares : Average [>25% and <50%] |
Aug 30,2024 |
Price(EOD): ₹ 701.05
This is the End-of-Day (EOD) Stock Price updated daily by 7 pm IST.
|
Pharmaceuticals & Drugs |
MCap: ₹ 3,365.04 Cr |
Industry Peers & Returns | 1W | 1M | 1Y |
SOLARA ACTIVE PHARMA SCIENCES | -2.1% | 12.2% | 108.9% |
SUN PHARMACEUTICAL INDUSTRIES | 2.7% | 6% | 62.4% |
CIPLA | 3.9% | 7.3% | 33.9% |
DR REDDYS LABORATORIES | 1.2% | 4.2% | 20.1% |
ZYDUS LIFESCIENCES | 1.8% | -9.5% | 80.1% |
DIVIS LABORATORIES | 3.2% | 3.5% | 37.8% |
FUNDAMENTAL ANALYSIS OF SOLARA ACTIVE PHARMA SCIENCES
 Y : Last Audited Annual/Yearly Data
TTM i.e. Trailing Twelve Months is calculated using last 4 quarterly data and is a good substitute to track last 4 Qtr Annual result before the subsequent year data is published and audited.
Learn More
VALUATION OF SOLARA ACTIVE PHARMA SCIENCES
 Ratio | Consolidated | |
---|---|---|
P/E P/B P/S |
-6
P/E Calculated based on Trailing Twelve Months (TTM) Earnings of Rs -561.31 Cr
[Latest Qtr - Jun2024 - Consolidated Results ] 3.6
P/B Calculated based on Book Value of Rs 933.91 Cr
[Latest Year - Mar2024 - Consolidated Results ] 2.52
P/S Calculated based on Trailing Twelve Months (TTM) Revenues of Rs 1,336.89 Cr
[Latest Qtr - Jun2024 - Consolidated Results ] |
|
Financial Ratios → |
Model | Discount(-)/ Premium(+) |
---|---|
EV/EBIDTA EV/Sales Price/Sales |
604% 252% 191% |
SHARE PRICE MOMENTUM OF SOLARA ACTIVE PHARMA SCIENCES
SOLARA ACTIVE PHARMA SCIENCES vs SENSEX
DEBT OF SOLARA ACTIVE PHARMA SCIENCES
Year | Debt/Equity ratio | |
---|---|---|
Standalone | Consolidated | |
2023 2022 2021 Avg_3yrs |
0.67 0.67 0.38 0.57 |
0.67 0.67 0.38 0.57 |
[Last Annual Data : Mar2023]
|
||
Financial Ratios → |
PLEDGED PROMOTER SHARES OF SOLARA ACTIVE PHARMA SCIENCES
Pledged Promoter Shares |
49.06 % | |
---|---|---|
As on : Dec2023 | ||
If less than 25% | Good |
|
If between 25% and 50% | Neutral | |
If greater than 50% | Bad | |
Shareholding Pattern → |
QTRLY RESULTS OF SOLARA ACTIVE PHARMA SCIENCES
Consolidated | Q-o-Q | Y-o-Y |
---|---|---|
Revenue Op Profit Profit Before Tax Profit After Tax |
21.39% 329.51% 91.92% 94.73% |
3.17% 119.25% 54.16% 29.57% |
QtrlyTrend |
8 | |
Latest Qtr: Jun2024 | ||
Quarterly Result Analysis → |
SOLARA ACTIVE PHARMA SCIENCES related INDICES
BSE Indices | 1W | 1M | 1Y |
---|---|---|---|
S&P BSE HEALTHCARE | 2.5% | 7.5% | 54.8% |
S&P BSE ALLCAP | 1.2% | 1.2% | 40.7% |
S&P BSE MIDSMALLCAP | 1.1% | 1.4% | 56.7% |
S&P BSE SMALL CAP | 0.6% | 1.1% | 55% |
You may also like the below Video Courses
FAQ about SOLARA ACTIVE PHARMA SCIENCES
Is SOLARA ACTIVE PHARMA SCIENCES good for long term investment?
As on Aug 30,2024, the Fundamentals of SOLARA ACTIVE PHARMA SCIENCES look Average and hence you may wait for the results to improve to invest for long term ! See Financial Performance of SOLARA ACTIVE PHARMA SCIENCES . Please look at the other parameters such as Valuation, Price Momentum, News & Corporate Governance and/or consult an Investment Advisor before taking an investment decision!Is SOLARA ACTIVE PHARMA SCIENCES UnderValued or OverValued?
As on Aug 30,2024, SOLARA ACTIVE PHARMA SCIENCES is Over Valued based on the estimates of intrinsic value and hence may not be a good buying opportunity according to Share Valuation at this time!What is the Intrinsic Value of SOLARA ACTIVE PHARMA SCIENCES ?
As on Aug 30,2024, the Intrinsic Value of SOLARA ACTIVE PHARMA SCIENCES is Rs. 199.05 estimated based on Median of the 3 historical models.Fair Value [Median EV / EBIDTA Model] : Rs. 99.58
Fair Value [Median EV / Sales Model] : Rs. 199.05
Fair Value [Median Price / Sales Model] : Rs. 240.55
Estimated Median Fair Value of SOLARA ACTIVE PHARMA SCIENCES : Rs. 199.05
The fair value of any stock is always subjective and should, in no way, be taken as a recommendation to buy/sell the same.